Table 2.
Cox model estimates of the prognostic significance of each parameter for recurrence‐free survival
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P‐value | HR | 95% CI | P‐value | |
| HER2 | ||||||
| Positive | 3.43 | 1.50–7.23 | 0.005 | 2.94 | 1.18–6.90 | 0.022 |
| Negative | 1.00 | 1.00 | ||||
| Hormone receptora | ||||||
| Positive | 0.41 | 0.20–0.82 | 0.011 | 0.41 | 0.18–0.86 | 0.018 |
| Negative | 1.00 | 1.00 | ||||
| Histologic subtype | ||||||
| Pure | 1.00 | 0.013 | 0.01 | |||
| Mixed | 0.58 | 0.34–0.90 | 0.54 | 0.30–0.87 | ||
| FIGO stage | ||||||
| I or II | 1.00 | 0.013 | 1.00 | 0.19 | ||
| III or IV | 1.54 | 1.09–2.19 | 1.28 | 0.88–1.88 | ||
| Myometrial invasion (%) | ||||||
| ≤50 | 1.00 | 0.0001 | 1.00 | 0.97 | ||
| >50 | 2.00 | 1.40–2.97 | 1.02 | 0.49–1.98 | ||
| Lymph node metastasis | ||||||
| Positive | 1.86 | 1.07–3.03 | 0.085 | |||
| Negative | 1.00 | |||||
| Unknown | 0.78 | 0.48–1.24 | ||||
| Lymph–vascular space involvement | ||||||
| Positive | 1.87 | 1.31–2.77 | 0.0005 | 1.51 | 0.80–3.06 | 0.21 |
| Negative | 1.00 | 1.00 | ||||
a
Hormone receptor expression was classified as positive when the patient was positive for either estrogen or progesterone receptors. HR, hazards ratio; CI, confidence interval; HER2, human epidermal growth factor receptor type 2; FIGO, International Federation of Gynecology and Obstetrics.